Ruxolitinib-Azacitidine Combination Shows ‘Synergistic Efficacy’ for Myelofibrosis

A single-arm, open-label, phase II study of ruxolitinib plus azacitidine in patients with myelofibrosis demonstrated a more than a 50% reduction in palpable spleen length in 62% of patients at 24 weeks, with 95% maintaining this at 48 weeks. In addition, at 24 months, bone marrow reticulin fibrosis grade improved in 57% of patients.

 HemOnc Today

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.